keyword
MENU ▼
Read by QxMD icon Read
search

Splenic B-cell lymphoma

keyword
https://www.readbyqxmd.com/read/29692893/management-of-gastrosplenic-fistula-in-the-emergency-setting-a-case-report-and-review-of-the-literature
#1
Amit Frenkel, Yoav Bichovsky, Zvi H Perry, Jochanan Peiser, Aviel Roy-Shapira, Evgeni Brotfain, Leonid Koyfman, Yair Binyamin, Karen Nalbandyan, Moti Klein
Introduction: A gastrosplenic fistula (GSF) is a very rare complication that arises mainly from a splenic or gastric large cell lymphoma. The proximity of the gastric fundus to the enlarged fragile spleen may facilitate the fistulisation. This complication can lead to massive bleeding, which, though uncommon, may be lethal. We present a patient with massive upper gastrointestinal bleeding secondary to a GSF. Case presentation: We present a 48-year-old man with a refractory diffuse large B-cell lymphoma who was admitted to our hospital due to hematemesis...
May 2018: Annals of Medicine and Surgery
https://www.readbyqxmd.com/read/29662866/a-rare-case-of-splenic-diffuse-red-pulp-small-b-cell-lymphoma-sdrpl-a-review-of-the-literature-on-primary-splenic-lymphoma-with-hairy-cells
#2
Tanush Vig, Thomas Alex Kodiatte, Marie Therese Manipadam, Fouzia Nambiathayil Aboobacker
No abstract text is available yet for this article.
March 2018: Blood Research
https://www.readbyqxmd.com/read/29661716/small-cell-lymphocytic-variant-of-marginal-zone-lymphoma-a-distinct-form-of-marginal-zone-lymphoma-derived-from-na%C3%A3-ve-b-cells-as-a-cutaneous-counterpart-to-the-na%C3%A3-ve-marginal-zone-lymphoma-of-splenic-origin
#3
REVIEW
Cynthia M Magro, Luke C Olson
Primary cutaneous marginal zone lymphoma most commonly represents an indolent form of cutaneous B cell lymphoma. However, epidermotropic marginal zone lymphoma, blastic marginal zone lymphoma and B cell dominant variants without isotype switching can be associated with extracutaneous dissemination. The presumptive cell of origin is a post germinal center B cell with plasmacytic features. In the extracutaneous setting, however, a naïve B cell origin has been proposed for a subset of marginal zone lymphomas, notably splenic marginal zone lymphoma...
February 21, 2018: Annals of Diagnostic Pathology
https://www.readbyqxmd.com/read/29628774/management-of-relapsed-refractory-marginal-zone-lymphoma-focus-on-ibrutinib
#4
REVIEW
Nathan M Denlinger, Narendranath Epperla, Basem M William
Marginal zone lymphomas (MZLs) consist of a diverse family of malignancies, which are derived from B-cells. The disease subtypes are recognized extranodal, nodal, and splenic MZLs. The disease characteristics, clinical course, and treatment vary considerably based on the site of involvement. In 2017, the US Food and Drug Administration approved ibrutinib, a first in class Bruton's tyrosine kinase inhibitor that revolutionized the care of chronic lymphocytic leukemia patients; for, the treatment of relapsed/refractory MZL based on pivotal open-label Phase II trial demonstrated an overall response rate of 48%, with a complete response rate of 3%, median progression-free survival of 14...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29618685/-splenic-diffuse-red-pulp-small-b-cell-lymphoma-diagnosed-by-splenectomy-initially-mimicking-hairy-cell-leukemia-japanese-variant
#5
Yukika Yamada, Miyoko Miura, Mayu Tagari, Kazuo Oshimi, Tomokazu Shiragata, Wataru Suga, Tatsurou Takahashi, Kazuyoshi Shimizu, Kouichi Ohshima, Keizou Kajiwara
A 62-year-old man presented to the hospital with thrombocytopenia, and splenomegaly was detected. His blood films prepared by natural air drying revealed medium-sized lymphocytes with unevenly distributed large and small villous projections. The cytoplasm was basophilic, nuclei were oval with clumped chromatin, and nucleoli were absent in most cells. Immune phenotypes CD19+, CD20+, CD11c+, FMC7+, IgM+, and Igκ+ were detected. TRAP stain appeared negative, IgH JH chain genes were monoclonally rearranged, and BRAF V600E mutation was not detected...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/29523661/idelalisib-and-rituximab-in-17p-deletion-positive-splenic-marginal-zone-lymphoma
#6
Aby Z Philip
Splenic marginal zone lymphoma (SMZL) is a rare indolent B-cell malignancy involving the spleen and bone marrow. Various cytogenetic abnormalities with prognostic value have been identified in SMZL. Complexity of karyotype, 14q aberrations, and TP53 deletions have been found to be poor prognostic indicators. We report an unusual case of SMZL with a complex karyotype including 17p deletion, primarily refractory to 2 chemoimmunotherapy regimens, that responded well to treatment with phosphatidylinositol-3-kinase delta (PI3Kδ) inhibitors idelalisib and rituximab...
March 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29461617/jak-stat5-signaling-pathway-inhibitor-ruxolitinib-reduces-airway-inflammation-of-neutrophilic-asthma-in-mice-model
#7
R-F Li, G-F Wang
OBJECTIVE: The aim of this study was to explore the role of JAK/STAT signaling pathway inhibitor Ruxolitinib in neutrophilic airway inflammation and its possible immunological mechanism. MATERIALS AND METHODS: A total of 60 female C57BL/6 mice were randomly divided into neutrophilic asthma (NA) group, Ruxolitinib-treated (Ruxo) group and control (Con) group. Mice in NA and Ruxo groups were sensitized with ovalbumin (OVA) and excited to establish mice models of asthma...
February 2018: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29460043/low-rate-of-spleen-involvement-in-sporadic-burkitt-lymphoma-at-staging-on-pet-ct
#8
Tima Davidson, Eldar Priel, Ginette Schiby, Stephen Raskin, Bar Chikman, Ella Nissan, Ohad Benjamini, Johnatan Nissan, Elinor Goshen, Simona Ben-Haim, Ophira Salomon, Abraham Avigdor
BACKGROUND: Burkitt lymphoma is a highly aggressive B cell non-Hodgkin lymphoma. Cross-sectional imaging techniques that are used to detect liver and spleen involvement by lymphoma have high rates of false negative and false positive findings, and as such may reduce the accuracy of staging. PURPOSE: This retrospective study evaluated the use of FDG PET-CT in determining splenic involvement at staging, in a relatively large cohort of adult patients with the sporadic form of Burkitt lymphoma (SBL)...
February 19, 2018: Abdominal Radiology
https://www.readbyqxmd.com/read/29452668/should-rituximab-replace-splenectomy-in-the-management-of-splenic-marginal-zone-lymphoma
#9
REVIEW
Christina Kalpadakis, Gerassimos A Pangalis, Maria K Angelopoulou, Sotirios Sachanas, Theodoros P Vassilakopoulos
SMZL is a relatively rare low grade B-cell lymphoma, characterized usually by an indolent clinical behavior. Since there is no prospective randomized trials to establish the best treatment approach, decision on therapeutic management should be based on the available retrospective series. Based on these data, rituximab and splenectomy appear to be the most effective. Splenectomy represented the standard treatment modality until early 2000s. More than 90% of the patients present quick amelioration of splenomegaly related symptoms along with improvement of cytopenias related to hypersplenism...
March 2018: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/29419478/-18-f-fludarabine-pet-for-lymphoma-imaging-first-in-man-study-in-dlbcl-and-cll-patients
#10
Sylvain Chantepie, Narinée Hovhannisyan, Stéphane Guillouet, Jean-Pierre Pelage, Méziane Ibazizene, Caroline Bodet-Milin, Thomas Carlier, Anne-Claire Gac, Emilie Réboursière, Jean-Pierre Vilque, Françoise Kraeber-Bodéré, Alain Manrique, Gandhi Damaj, Michel Leporrier, Louisa Barré
This is the first in-man clinical study of 18 F-fludarabine which is a radiopharmaceutical for PET imaging in lymphoma where many issues remain controversial with the standard radiotracer 18 F-FDG. Methods: 18 F-Fludarabine-PET(/CT) was performed in 10 patients: five with diffuse large B-cell lymphoma (DLBCL) and five with chronic lymphocytic leukemia (CLL). The biodistribution, and radiation dosimetry of 18 F-fludarabine have also been evaluated. Six successive partial body PET scans were acquired for 250 min after intravenous 4 MBq/kg bolus of 18 F-fludarabine...
February 1, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29417312/lessons-learned-from-splenic-infarcts-with-fever-of-unknown-origin-fuo-culture-negative-endocarditis-cne-or-malignancy
#11
REVIEW
Burke A Cunha, Bertamaria Dieguez, Alena Varantsova
Culture negative endocarditis (CNE) is a common concern in patients with fever, heart murmur, cardiac vegetation, and negative blood cultures. The diagnosis of CNE is not based only on negative blood cultures and a cardiac vegetation. The clinical definition of CNE is based on negative blood cultures plus the findings of culture positive infective endocarditis (IE), e.g., fever, cardiac vegetation, splenomegaly, peripheral manifestations. Because embolic splenic infarcts may occur with culture positive IE, some may assume that splenic infarcts are a sign of CNE...
February 7, 2018: European Journal of Clinical Microbiology & Infectious Diseases
https://www.readbyqxmd.com/read/29416725/hepatitis-c-virus-infection-is-an-independent-prognostic-factor-in-follicular-lymphoma
#12
Joji Shimono, Hiroaki Miyoshi, Takeharu Kato, Takeshi Sugio, Kohta Miyawaki, Tomohiko Kamimura, Takuto Miyagishima, Tetsuya Eto, Yoshitaka Imaizumi, Koji Kato, Koji Nagafuji, Koichi Akashi, Masao Seto, Takanori Teshima, Koichi Ohshima
Hepatitis C virus (HCV) is a single-stranded RNA virus that not only affects hepatocytes, by B cells as well. It is thought that HCV is involved in the onset of B-cell lymphoma. The clinicopathological characteristics of HCV-positive diffuse large B-cell lymphoma (DLBCL) and HCV-positive splenic marginal zone lymphoma (SMZL) are known, but there has been no report on HCV-positive follicular lymphoma (FL). In this study, the clinicopathological characteristics of HCV-positive FL were examined in 263 patients with FL who were classified into a HCV-positive group with HCV antibody and negative groups without one...
January 5, 2018: Oncotarget
https://www.readbyqxmd.com/read/29377231/epidermotropic-presentation-by-splenic-b-cell-lymphoma-the-importance-of-clinical-pathologic-correlation
#13
Amin A Hedayat, Joi B Carter, Frederick Lansigan, Robert E LeBlanc
There are exceedingly rare reports of patients with epidermotropic B-cell lymphomas. A subset presented with intermittent, variably pruritic papular eruptions and involvement of their spleens, peripheral blood and bone marrow at the time of diagnosis. Furthermore, some experienced an indolent course despite dissemination of their lymphomas. We report a 66-year-old woman with a 12-year history of intermittent eruptions of non-pruritic, salmon-colored papules on her torso and proximal extremities that occurred in winter and resolved with outdoor activity in spring...
April 2018: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/29356737/rare-variant-of-intravascular-large-b-cell-lymphoma-with-hemophagocytic-syndrome
#14
Joseph S Donald, Nick Barnthouse, Delphine L Chen
Intravascular lymphoma (IVL) is a rare subtype of diffuse large B-cell lymphoma characterized by a clonal proliferation of lymphocytes restricted to the intravascular space. We present the case of a 60-year-old man with hemophagocytic syndrome secondary to IVL. F-FDG PET/CT demonstrated hepatosplenomegaly with marked diffuse hepatic, splenic, and bone marrow hypermetabolism. The case report illustrates the imaging findings of this uncommon variant of IVL.
April 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29348316/evaluation-of-next-generation-anti-cd20-antibodies-labeled-with-zirconium-89-in-human-lymphoma-xenografts
#15
Jason T Yoon, Mark S Longtine, Bernadette V Marquez-Nostra, Richard L Wahl
Radioimmunotherapies with monoclonal antibodies (mAbs) to the B-lymphocyte antigen 20 (CD20) are effective treatments for B-cell lymphomas, but United States Food and Drug Administration (FDA)-approved radioimmunotherapies exclusively use radiolabeled murine antibodies, potentially limiting re-dosing. The FDA recently approved two unlabeled anti-CD20 monoclonal antibodies, obinutizumab and ofatumumab, termed "next generation" as they are humanized (obinituzumab) or fully human (ofatumumab), thus potentially allowing a greater potential for re-dosing than with previous generation anti-CD20 antibodies, including rituximab (chimeric) and tositumumab (murine) which contain more murine peptide sequences...
January 18, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29335928/ct-imaging-of-primary-pancreatic-lymphoma-experience-from-three-referral-centres-for-pancreatic-diseases
#16
Enrico Boninsegna, Giulia A Zamboni, Davide Facchinelli, Charikleia Triantopoulou, Sofia Gourtsoyianni, Maria Chiara Ambrosetti, Dino Veneri, Achille Ambrosetti, Roberto Pozzi Mucelli
PURPOSE: To describe CT characteristics of primary pancreatic lymphoma (PPL), a rare disease with features in common with adenocarcinoma. MATERIALS AND METHODS: Fourteen patients were enrolled. CT: unenhanced scan, contrast-enhanced pancreatic and venous phases. Image analysis: tumour location; peri-pancreatic vessel encasement; necrosis; enlarged lymph nodes; fat stranding; enlarged bile duct and pancreatic duct; neoplasm longest dimension, volume and density. RESULTS: Histopathological diagnoses: follicular non-Hodgkin lymphoma (5/14), diffuse large B-cell lymphoma (6/14) and high-grade B-cell lymphoma not otherwise specified (3/14)...
February 2018: Insights Into Imaging
https://www.readbyqxmd.com/read/29309299/comparison-of-myocyte-enhancer-factor-2b-versus-other-germinal-center-associated-antigens-in-the-differential-diagnosis-of-b-cell-non-hodgkin-lymphomas
#17
Erika M Moore, Steven H Swerdlow, Sarah E Gibson
Myocyte enhancer binding factor 2B (MEF2B) is a transcriptional activator of the BCL6 proto-oncogene in normal germinal center (GC) B-cells. Limited data exists concerning its expression in B-cell lymphomas, and comparison with other GC-associated antigens is lacking. Its role in the differential diagnosis of B-cell lymphomas, particularly in the distinction of follicular lymphoma (FL) versus marginal zone lymphoma (MZL), remains to be determined. We evaluated MEF2B expression, in comparison with additional GC markers, LIM domain-only transcription factor 2 (LMO2), and human GC-associated lymphoma (HGAL), in a variety of B-cell lymphomas, with particular emphasis on their utility in differentiating FL from MZL...
March 2018: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/29288421/first-line-treatment-with-bendamustine-and-rituximab-in-patients-with-intermediate-high-risk-splenic-marginal-zone-lymphomas
#18
Roberto Castelli, Luigi Bergamaschini, Giorgio Lambertenghi Deliliers
Splenic marginal zone lymphomas (SMZLs) are rare indolent B cell neoplasms that affect the spleen, bone marrow, and blood. Although they have an indolent course in the majority of patients, who have a median survival of 8-10 years, ∼ 30% may experience a worse outcome. The prognostic criteria of progression are lymph node and extra-nodal involvement, high lymphocyte counts, anaemia, and thrombocytopenia. The treatment of SMZLs include a "wait and watch strategy", splenectomy, and alkylating agents ± rituximab...
December 29, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29260925/effective-management-strategies-for-patients-with-marginal-zone-lymphoma
#19
Cecilia B Rosand, Kelly Valla, Christopher R Flowers, Jean L Koff
Marginal zone lymphoma (MZL) is an uncommon indolent lymphoma classified into subtypes based on primary site of involvement: splenic, nodal and extranodal. MZLs' relative rarity has largely precluded adoption of a standard management strategy. Here, we provide an overview of the epidemiology, clinical behavior and therapeutic approaches for each subtype. Biologic insights into lymphomagenesis have identified B-cell receptor signaling as a rational therapeutic target. Recent clinical data suggest that novel agents targeting this pathway, including the Bruton's tyrosine kinase inhibitor, ibrutinib, show significant promise in treatment of relapsed MZL...
December 20, 2017: Future Oncology
https://www.readbyqxmd.com/read/29246929/sarcoidosis-lymphoma-syndrome-a-diagnostic-dilemma
#20
Assad Oskuei, Lisa Hicks, Hasan Ghaffar, Victor Hoffstein
Sarcoidosis and lymphoma are generally thought of as being two mutually exclusive diseases that need to be considered in the differential diagnosis of patients with hilar/mediastianal lymphadenopathy. However, there are rare patients in whom both of these diseases coexist. These patients constitute a diagnostic challenge because their presentation (ie, clinical symptoms, imaging abnormalities and even pathology) may all be atypical when each individual disease is considered separately. In this report, we describe a patient who presented with such atypical features and was eventually diagnosed as having both sarcoidosis and a B-cell lymphoma with features of splenic marginal zone lymphoma (SMZL) simultaneously...
December 14, 2017: BMJ Case Reports
keyword
keyword
23230
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"